Integrated multi-omics elucidates PRNP knockdown-mediated chemosensitization to gemcitabine in pancreatic ductal adenocarcinoma
This study demonstrates that <i>PRNP</i> is a key regulator of gemcitabine resistance in PDAC, modulating EMT, ferroptosis, and the tumor immune microenvironment. Targeting <i>PRNP</i> represents a promising therapeutic strategy to reverse gemcitabine resistance and may hold significant potential for clinical translation in PDAC treatment.
Authors
- Yu‐Wei Wu (ORCID: https://orcid.org/0000-0002-5603-1194)
- Jing Chen (ORCID: https://orcid.org/0000-0001-7721-2608)
- Bing Qi (ORCID: https://orcid.org/0009-0006-4347-1429)
- Xuanrui Zhang (ORCID: https://orcid.org/0009-0001-5676-0127)
- L Duan
- Yangbo Wei
- Ning Wang (ORCID: https://orcid.org/0000-0003-2016-5630)
Institutions
- North China University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1667835
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00